- Headquarters
- New York, New York
- Employees
- 1–10
- Founded
- 2024
- Business Model
- B2B
- Website
- hexemb.io
- Total Funding
- $17.9M
- Last Round
- $10.4M SeedApr 2026
- Rounds
- 2
About
heXembio is a longevity therapeutics company developing the world's first rejuvenated hematopoietic stem cell therapy. Its platform restores the regenerative power of aged blood stem cells using a synthetic biology approach validated in peer-reviewed research published in Nature. The technology targets aging, immune health, and hematological conditions.
Summary
heXembio is a Biotech company based in New York, United States, founded in 2024. It has raised $17.9M in total across 2 rounds, most recently a $10.4M Seed round in Apr 2026. Investors include Draper Associates, SOSV and Zentynel.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2026
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company